Tag: pseudoprogression

Posted on

Long-term tumor control after Gamma Knife radiosurgery for sporadic vestibular schwannoma

J Neurosurg 144:965–971, 2026

This clinical study evaluates long-term tumor control after single-fraction Gamma Knife stereotactic radiosurgery (SRS) for sporadic vestibular schwannoma in 749 adults treated from 2000–2022, reporting Kaplan–Meier control rates of 100%, 98%, 96%, 92%, and 91% at 1, 3, 5, 10, and 15 years respectively. Patient demographics, SRS dosing, and complication rates—including low persistent facial paresis—are summarized with statistical analysis and clear definitions for growth, pseudoprogression, and salvage.

The authors detail three post-SRS tumor behavior patterns, finding 13% pseudoprogression (mostly within 5 years) and 42 salvage treatments (median 3.7 years), and conclude that SRS offers durable control while emphasizing the need for prolonged surveillance and nuanced clinical decision-making about retreatment.

Objective Assess long-term efficacy of single-fraction stereotactic radiosurgery (SRS) as primary treatment for adult, treatment-naïve sporadic vestibular schwannoma (Gamma Knife), treated from 2000–2022.

Cohort 749 adults included; 76% had tumors extending into the cerebellopontine angle (CPA) at SRS; median age 62; 50% women; 99% had House-Brackmann (HB) grade I facial nerve function at SRS.

Long-term tumor control Tumor control after SRS remained high: 100% (1 yr), 98% (3 yr), 96% (5 yr), 92% (10 yr), and 91% (15 yr).

Radiosurgical failure/salvage 42 patients required salvage (35 microsurgery, 7 repeat SRS), median 3.7 years post-SRS; 3 salvage treatments occurred >10 years after SRS, indicating late failures can occur.

Risk factors Age, macrocystic tumor presence, and treated tumor volume were not significantly associated with risk of salvage in univariable analysis.

Post-SRS tumor patterns Three post-SRS behaviors were observed: (1) stability/shrinkage, (2) pseudoprogression (growth then stability/shrinkage), and (3) continued growth without stability at last follow-up.

Pseudoprogression timing 13% experienced pseudoprogression; all but 4 showed it by year 5 post-SRS, though some initial growth occurred later (e.g., 5.1–8.6 years) with subsequent stability on follow-up imaging.

Conclusion/implication SRS provides durable control through 15 years for most patients (91%), but ongoing long-term surveillance is needed because failures may occur even beyond 10 years and pseudoprogression can be seen out to ≥5 years.

Posted on

Association Between Pseudoprogression of Vestibular Schwannoma After Radiosurgery and Radiological Features of Solid and Cystic Components

Neurosurgery 93:1383–1392, 2023

The pathophysiology of vestibular schwannoma (VS) pseudoprogression after Gamma Knife radiosurgery (GKRS) remains unclear. Radiological features in pretreatment magnetic resonance images may help predict VS pseudoprogression. This study used VS radiological features quantified using an automated segmentation algorithm to predict pseudoprogression after GKRS treatment.

METHODS: This is a retrospective study comprising 330 patients with VS who received GKRS. After image preprocessing and T2W/contrast-enhanced T1-weighted image (CET1W) image generation, with fuzzy C-means clustering, VSs were segmented into solid and cystic components and classified as solid and cystic. Relevant radiological features were then extracted. The response to GKRS was classified into “nonpseudoprogression” and “pseudoprogression/fluctuation”. The Z test for two proportions was used to compare solid and cystic VS for the likelihood of pseudoprogression/fluctuation. Logistic regression was used to assess the correlation between clinical variables and radiological features and response to GKRS.

RESULTS: The likelihood of pseudoprogression/fluctuation after GKRS was significantly higher for solid VS compared with cystic VS (55% vs 31%, P < .001). For the entire VS cohort, multivariable logistic regression revealed that a lower mean tumor signal intensity (SI) in T2W/CET1W images was associated with pseudoprogression/fluctuation after GKRS (P = .001). For the solid VS subgroup, a lower mean tumor SI in T2W/CET1W images (P = .035) was associated with pseudoprogression/fluctuation after GKRS. For the cystic VS subgroup, a lower mean SI of the cystic component in T2W/ CET1W images (P = .040) was associated with pseudoprogression/fluctuation after GKRS.

CONCLUSION: Pseudoprogression is more likely to occur in solid VS compared with cystic VS. Quantitative radiological features in pretreatment magnetic resonance images were associated with pseudoprogression after GKRS. In T2W/ CET1W images, solid VS with a lower mean tumor SI and cystic VS with a lower mean SI of cystic component were more likely to have pseudoprogression after GKRS. These radiological features can help predict the likelihood of pseudoprogression after GKRS.

Posted on

Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know

J Neurosurg 139:748–759, 2023

Management of patients with glioblastoma (GBM) is complex and involves implementing standard therapies including resection, radiation therapy, and chemotherapy, as well as novel immunotherapies and targeted small-molecule inhibitors through clinical trials and precision medicine approaches. As treatments have advanced, the radiological and clinical assessment of patients with GBM has become even more challenging and nuanced.

Advances in spatial resolution and both anatomical and physiological information that can be derived from MRI have greatly improved the noninvasive assessment of GBM before, during, and after therapy.

Identification of pseudoprogression (PsP), defined as changes concerning for tumor progression that are, in fact, transient and related to treatment response, is critical for successful patient management. These temporary changes can produce new clinical symptoms due to mass effect and edema. Differentiating this entity from true tumor progression is a major decision point in the patient’s management and prognosis.

Providers may choose to start an alternative therapy, transition to a clinical trial, consider repeat resection, or continue with the current therapy in hopes of resolution. In this review, the authors describe the invasive and noninvasive techniques neurosurgeons need to be aware of to identify PsP and facilitate surgical decision-making.

Proudly powered by WordPress